Noninflammatory adjuvant improving dendritic cell priming and anti-PD-L1 efficacy

被引：0
|
作者：
Seya, Tsukasa [1 ]
Takeda, Yohei [1 ]
Matsumoto, Misako [1 ]
机构：
[1] Hokkaido Univ, Sch Med, Vaccine Immunol, Sapporo, Hokkaido, Japan
来源：
CANCER SCIENCE | 2018年 / 109卷
关键词：
Immunotherapy; Vaccine;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ML10
引用
收藏
页码：551 / 551
页数：1
相关论文
共 50 条
  • [1] Dendritic Cell-Derived Exosomes Increase the Efficacy of anti-PD-L1 Antibody in Melanoma Model
    Chao, Po Kuan
    Hsu, Tsu-An
    CANCER SCIENCE, 2018, 109 : 1322 - 1322
  • [2] Improving efficacy and reducing toxicity of anti-PD-L1 treatment: T-cells as delivery vehicles for anti-PD-L1 blocking nanobodies
    Petit, P-F.
    Zhu, J.
    van den Eynde, B. J.
    ANNALS OF ONCOLOGY, 2020, 31 : S1425 - S1425
  • [3] Benefit with anti-PD-L1
    Diana Romero
    Nature Reviews Clinical Oncology, 2017, 14 : 71 - 71
  • [4] Dendritic cell-intrinsic PTPN22 negatively regulates antitumor immunity and impacts anti-PD-L1 efficacy
    Acero-Bedoya, Santiago
    Higgs, Emily F.
    Martinez, Anna C.
    Tonea, Ruxandra
    Gajewski, Thomas F.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (10)
  • [5] Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
    Jiming Chen
    Jie Yang
    Wenhui Wang
    Danfeng Guo
    Chengyan Zhang
    Shibo Wang
    Xinliang Lu
    Xiaofang Huang
    Pingli Wang
    Gensheng Zhang
    Jing Zhang
    Jianli Wang
    Zhijian Cai
    Cellular & Molecular Immunology, 2022, 19 : 1290 - 1301
  • [6] Tumor extracellular vesicles mediate anti-PD-L1 therapy resistance by decoying anti-PD-L1
    Chen, Jiming
    Yang, Jie
    Wang, Wenhui
    Guo, Danfeng
    Zhang, Chengyan
    Wang, Shibo
    Lu, Xinliang
    Huang, Xiaofang
    Wang, Pingli
    Zhang, Gensheng
    Zhang, Jing
    Wang, Jianli
    Cai, Zhijian
    CELLULAR & MOLECULAR IMMUNOLOGY, 2022, 19 (11) : 1290 - 1301
  • [7] A new combination immunotherapy approach with anti-PD-L1 and HER2/neu loaded dendritic cell vaccine along with saponin adjuvant
    Ozverel, C. S.
    Karaboz, I.
    Nalbantsoy, A.
    EUROPEAN JOURNAL OF CANCER, 2018, 92 : S6 - S7
  • [8] Hyperprogressive disease with anti-PD-1 and anti-PD-L1
    Brower, Vicki
    LANCET ONCOLOGY, 2016, 17 (12): : E527 - E527
  • [9] IMMUNOTHERAPY Benefit with anti-PD-L1
    Romero, Diana
    NATURE REVIEWS CLINICAL ONCOLOGY, 2017, 14 (02) : 70 - 70
  • [10] Efficacy and safety of cosibelimab, an anti-PD-L1 antibody, in metastatic cutaneous squamous cell carcinoma
    Clingan, Philip
    Ladwa, Rahul
    Brungs, Daniel
    Harris, Dean Laurence
    McGrath, Margaret
    Arnold, Susan
    Coward, Jermaine
    Fourie, Samuel
    Kurochkin, Andriy
    Malan, Daniel R.
    Mant, Andrew
    Sharma, Vinay
    Shue, Hong
    Tazbirkova, Andrea
    Berciano-Guerrero, Miguel-Angel
    Charoentum, Chaiyut
    Dalle, Stephane
    Dechaphunkul, Arunee
    Dudnichenko, Oleksandr
    Koralewski, Piotr
    Lugowska, Iwona
    Montaudie, Henri
    Munoz-Couselo, Eva
    Sriuranpong, Virote
    Oliviero, James
    Desai, Jayesh
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (10)
12345